0.600
0.03 (4.95%)
| Previous Close | 0.572 |
| Open | 0.551 |
| Volume | 86,824 |
| Avg. Volume (3M) | 222,687 |
| Market Cap | 14,825,856 |
| Price / Sales | 34.02 |
| Price / Book | 2.19 |
| 52 Weeks Range |
| Profit Margin | -147.39% |
| Operating Margin (TTM) | -191.83% |
| Diluted EPS (TTM) | -0.050 |
| Quarterly Revenue Growth (YOY) | -34.30% |
| Total Debt/Equity (MRQ) | 4.01% |
| Current Ratio (MRQ) | 12.40 |
| Levered Free Cash Flow (TTM) | -1.48 M |
| Return on Assets (TTM) | -11.55% |
| Return on Equity (TTM) | -20.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Pheton Holdings Ltd | - | - |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Average | 0.17 |
|
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 95.17% |
| % Held by Institutions | 0.27% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |